Minoryx Therapeutics SL of Spain has raised €51 million in order to prepare for the regulatory review and possible market launch of its drug leriglitazone for the rare orphan disease X-linked adrenoleukodystrophy (X-ALD). The company is preparing a marketing authorisation application for the European Medicines Agency and holding pre-registration talks with the US Food and Drug Administration. The EU filing would be directed at treating adult male patients with the X-ALD phenotype adrenomyeloneuropathy (AMN).
